Ardea Biosciences, Inc. announced the relocation of the company's corporate headquarters and research laboratories to San Diego. The new facility will be in the Sorrento Valley and will house the company's research, preclinical and clinical development, pharmaceutical sciences and administrative operations.

"Moving our two southern California facilities to San Diego's biotechnology corridor is integral to our future growth and success, uniting the organization while providing access to a wealth of biotechnology and pharmaceutical industry expertise," said Barry D. Quart, PharmD, president and CEO, Ardea Biosciences. "We look forward to becoming an important contributor to the San Diego community at large."

Ardea Biosciences of San Diego, California is a biotechnology company focused on the discovery and development of small-molecule therapeutics in virology, oncology and inflammation. The company has two product candidates in clinical development and several others in preclinical development. Ardea's most advanced clinical development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a phase IIa study for the treatment of HIV.